Intelligence · Clinical Development
Pipeline search results
Programs matching “alcohol” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 117 pipeline programs matching "alcohol" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
ALG-055009
Aligos Therapeutics
NASH - Nonalcoholic Steatohepatitis
1 trial -
ALN-HSD
Alnylam Netherlands B.V.
Nonalcoholic Steatohepatitis
1 trial -
ALN-PNP
Regeneron UK Limited
Nonalcoholic Fatty Liver Disease (NAFLD)
1 trial -
Alcohol
BRIGHT MINDS BIOSCIENCES INC.
Opioid Use
1 trial -
Alcohol
BRIGHT MINDS BIOSCIENCES INC.
Alcohol Drinking
1 trial -
Alcohol + Caffeine Beverage
BRIGHT MINDS BIOSCIENCES INC.
Alcohol or Other Drugs Effects
1 trial -
Anti-human CCL24 monoclonal antibody (CM-101) - Part One
Chemomab Therapeutics
Nonalcoholic Fatty Liver Disease
1 trial -
CM-101
Chemomab Therapeutics
Nonalcoholic Steatohepatitis (NASH)
1 trial -
Chinese tea flavor liquor
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Alcohols
1 trial -
Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 40µg
BioXcel Therapeutics
Alcohol Use Disorder (AUD)
1 trial -
EDP-297
ENANTA PHARMACEUTICALS INC
NASH - Nonalcoholic Steatohepatitis With Liver Fibrosis
1 trial -
EDP-305
ENANTA PHARMACEUTICALS INC
NASH - Nonalcoholic Steatohepatitis
2 trials -
Evaluate the effects of Environmental Enrichment (EE) on alcohol consumption
BRIGHT MINDS BIOSCIENCES INC.
Alcohol Use Disorder
1 trial -
Fluconazole
ENANTA PHARMACEUTICALS INC
NASH - Nonalcoholic Steatohepatitis
1 trial -
GR-MD-02
GALECTIN THERAPEUTICS INC
Non-Alcoholic Steatohepatitis (NASH)
1 trial -
HEC169584 capsule
Sunshine Guojian Pharmaceutical (Shanghai) Co.,
Non - Alcoholic Steatohepatitis
1 trial -
HEC96719
Sunshine Guojian Pharmaceutical (Shanghai) Co.,
Non-alcoholic Fatty Liver Disease
1 trial -
HEC96719
Sunshine Guojian Pharmaceutical (Shanghai) Co.,
Nonalcoholic Steatohepatitis (NASH)
1 trial -
HEC96719 tablets
Sunshine Guojian Pharmaceutical (Shanghai) Co.,
Nonalcoholic Steatohepatitis (NASH)
1 trial -
MK-7480 Multiple Ascending Dose Study in Healthy Participants
Merck Sharp and Dohme
Non-alcoholic steatohepatitis
1 trial -
Minocycline
United Therapeutics Europe Ltd
Alcohol Dependence
1 trial -
Miricorilant
CORCEPT THERAPEUTICS INC
Non-alcoholic Steatohepatitis (NASH)
1 trial -
Miricorilant 150 mg
CORCEPT THERAPEUTICS INC
Nonalcoholic Steatohepatitis (NASH)
1 trial -
NALTR-17-24
Lacuna Pharma Pty Ltd
Alcohol dependence
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.